Aspirin for primary prevention of vascular disease in people with diabetes.

Aspirin for primary prevention of vascular disease in people with diabetes.

Détails bibliographiques
Auteurs principaux:	Haynes, R, Bowman, L, Armitage, J
Format:	Journal article
Langue:	English
Publié:	2009

Documents similaires

Aspirin in the primary prevention of vascular disease Reply
par: Baigent, C, et autres
Publié: (2009)

Aspirin in the primary prevention of vascular disease Reply
par: Baigent, C, et autres
Publié: (2009)

Effects of aspirin for primary prevention in persons with diabetes mellitus
par: Bowman, L, et autres
Publié: (2018)

Aspirin for primary prevention of cardiovascular disease in diabetes
par: Ying Xing, et autres
Publié: (2019-07-01)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
par: Bowman, L, et autres
Publié: (2017)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
par: Parish, S, et autres
Publié: (2022)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
par: Sammons, E, et autres
Publié: (2024)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
par: Algra Ale, et autres
Publié: (2000-11-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
par: Mant, J, et autres
Publié: (2021)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
par: Price, H, et autres
Publié: (2009)

Role of aspirin in primary prevention of cardiovascular disease
par: Patrono, C, et autres
Publié: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
par: VanWormer JJ, et autres
Publié: (2014-12-01)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
par: Baigent, C, et autres
Publié: (2009)

Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)
par: Hamzah Khan, et autres
Publié: (2021-12-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
par: Hennekens, C, et autres
Publié: (1989)

Application of aspirin in the primary prevention of stroke
par: Zhao YANG, et autres
Publié: (2015-02-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
par: Yinong Chen, et autres
Publié: (2021-09-01)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
par: Athena L. Huang, et autres
Publié: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
par: Athena L. Huang, MD, et autres
Publié: (2023-09-01)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
par: Fernández-de-Bobadilla Jaime, et autres
Publié: (2007-10-01)

Aspirin for prevention of cancer and cardiovascular disease.
par: Rose, P, et autres
Publié: (2011)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
par: Eleni Giannopoulou, et autres
Publié: (2024-12-01)

PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN DIABETES MELLITUS: THE ROLE OF ASPIRIN
par: L. A. Strizhakov
Publié: (2012-04-01)

Prevention. Aspirin in primary prevention--good news and bad news.
par: Hennekens, C, et autres
Publié: (2012)

Prevention: Aspirin in primary prevention-good news and bad news
par: Hennekens, C, et autres
Publié: (2012)

The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
par: Soo Hyun Kang, et autres
Publié: (2025-01-01)

Aspirin for the Primary Prevention of Vascular Ischemic Events: An Updated Systematic Review and Meta-analysis to Support Shared Decision-Making
par: Chloë Laferrière, MD, et autres
Publié: (2023-12-01)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
par: Hamzah Khan, et autres
Publié: (2022-08-01)

Aspirin for primary prevention of cardiovaascular events: what are the evidances?
par: Yenny Yenny
Publié: (2019-08-01)

6 voices in 10 minutes: Aspirin in primary prevention
par: Carlos Buso
Publié: (2020-11-01)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
par: Xie W, et autres
Publié: (2019-09-01)

Analysis of the Dilemma Involving Statins and Aspirin as Primary Prevention Alternatives in Cardiovascular Disease
par: Henry Sutanto
Publié: (2017-10-01)

CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES
par: P. J. Dovgalevsky, et autres
Publié: (2016-01-01)

ASPIRIN FOR PRIMARY PREVENTION IN HIGH-RISK TYPE 2 DIABETES: INSIGHTS FROM THE ACCORD TRIAL
par: Juliana H. Namutebi, MD, MS
Publié: (2024-09-01)

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
par: Catalano, M, et autres
Publié: (2007)

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials
par: Offer, A, et autres
Publié: (2019)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
par: Aung, T, et autres
Publié: (2017)

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease
par: Hadar Haim-Pinhas, et autres
Publié: (2022-10-01)

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
Publié: (2005-12-01)

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
par: Randall S Stafford, et autres
Publié: (2005-12-01)